A new review highlights growing evidence that cyclin-dependent kinase (CDK) inhibitors—already used in over a million breast cancer patients—could benefit other cancers through novel drug combinations ...
Worldwide, more than a million breast cancer patients have been treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, ...
Cyclin-dependent kinase (CDK)4/6 inhibitors are approved for the treatment of breast cancer, and they have more recently been used in patients with well ...
Researchers at the Francis Crick Institute have shown that the 'pacemaker' controlling yeast cell division lies inside the nucleus rather than outside it, as previously thought. Having the pacemaker ...
In this article, García-Vázquez et al. report valuable findings demonstrating that G2 and S phases expressed protein 1 (GTSE1), is a previously unappreciated non-pocket substrate of the cyclin ...
This important chronobiological study in mice suggests that light modulated activity of Cdk5 activity on the PKA-CaMK-CREB signaling pathway provides missing molecular mechanistic details to ...
DONGTAN, KOREA, October 7, 2024 - iLeadBMS, a spin-off biotech from Ildong Pharmaceutical Group, announced that it has received a notification from the US Food and Drug Administration (FDA) that its ...
NiKang Therapeutics Inc. (“NiKang”) is a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs. - Highly selective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results